83 related articles for article (PubMed ID: 25340469)
1. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.
Kumar M; Singh G; Sharma S; Gupta D; Bansal V; Arora V; Bhat M; Srivastava SK; Sapra S; Kharbanda S; Dinda AK; Singh H
Nanoscale; 2014 Nov; 6(23):14473-83. PubMed ID: 25340469
[TBL] [Abstract][Full Text] [Related]
2. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.
Kumar M; Gupta D; Singh G; Sharma S; Bhat M; Prashant CK; Dinda AK; Kharbanda S; Kufe D; Singh H
Cancer Res; 2014 Jun; 74(12):3271-81. PubMed ID: 24741005
[TBL] [Abstract][Full Text] [Related]
3. Intracellular delivery of peptide cargos using polyhydroxybutyrate based biodegradable nanoparticles: Studies on antitumor efficacy of BCL-2 converting peptide, NuBCP-9.
Kapoor S; Gupta D; Kumar M; Sharma S; Gupta AK; Misro MM; Singh H
Int J Pharm; 2016 Sep; 511(2):876-89. PubMed ID: 27492021
[TBL] [Abstract][Full Text] [Related]
4. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.
Kolluri SK; Zhu X; Zhou X; Lin B; Chen Y; Sun K; Tian X; Town J; Cao X; Lin F; Zhai D; Kitada S; Luciano F; O'Donnell E; Cao Y; He F; Lin J; Reed JC; Satterthwait AC; Zhang XK
Cancer Cell; 2008 Oct; 14(4):285-98. PubMed ID: 18835031
[TBL] [Abstract][Full Text] [Related]
5. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.
Watkins CL; Sayers EJ; Allender C; Barrow D; Fegan C; Brennan P; Jones AT
Mol Ther; 2011 Dec; 19(12):2124-32. PubMed ID: 21934653
[TBL] [Abstract][Full Text] [Related]
6. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Intracellular Delivery of NuBCP-9 by Conjugation with Oligoarginines Peptides in MDA-MB-231 Cells.
Wang W; Suga T; Hagimori M; Kuroda N; Fuchigami Y; Kawakami S
Biol Pharm Bull; 2018; 41(9):1448-1455. PubMed ID: 30175779
[TBL] [Abstract][Full Text] [Related]
8. Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition.
Yang J; Li Q; Zhou R; Zhou M; Lin X; Xiang Y; Xie D; Huang Y; Zhou Z
J Mater Chem B; 2021 Feb; 9(5):1336-1350. PubMed ID: 33443508
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy.
Gupta D; Kumar M; Tyagi P; Kapoor S; Tyagi A; Barman TK; Kharbanda S; Kufe D; Singh H
Nanomedicine; 2018 Jun; 14(4):1301-1313. PubMed ID: 29641982
[TBL] [Abstract][Full Text] [Related]
10. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging.
Park J; Kim S; Saw PE; Lee IH; Yu MK; Kim M; Lee K; Kim YC; Jeong YY; Jon S
J Control Release; 2012 Oct; 163(2):111-8. PubMed ID: 22964395
[TBL] [Abstract][Full Text] [Related]
11. Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
Gupta M; Chashoo G; Sharma PR; Saxena AK; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2014 Mar; 11(3):697-715. PubMed ID: 24512060
[TBL] [Abstract][Full Text] [Related]
12. Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery.
Morgan E; Gamble JT; Pearce MC; Elson DJ; Tanguay RL; Kolluri SK; Reich NO
Apoptosis; 2019 Jun; 24(5-6):529-537. PubMed ID: 30879165
[TBL] [Abstract][Full Text] [Related]
13. Complex of TNF-α and Modified Fe
Teo P; Wang X; Chen B; Zhang H; Yang X; Huang Y; Tang J
Cancer Biother Radiopharm; 2017 Dec; 32(10):379-386. PubMed ID: 29265918
[TBL] [Abstract][Full Text] [Related]
14. Reducible polyamidoamine-magnetic iron oxide self-assembled nanoparticles for doxorubicin delivery.
Chen J; Shi M; Liu P; Ko A; Zhong W; Liao W; Xing MM
Biomaterials; 2014 Jan; 35(4):1240-8. PubMed ID: 24239110
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
16. Nonpolymeric surface-coated iron oxide nanoparticles for in vivo molecular imaging: biodegradation, biocompatibility, and multiplatform.
Lee CM; Cheong SJ; Kim EM; Lim ST; Jeong YY; Sohn MH; Jeong HJ
J Nucl Med; 2013 Nov; 54(11):1974-80. PubMed ID: 24050935
[TBL] [Abstract][Full Text] [Related]
17. High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect.
Hayashi K; Ono K; Suzuki H; Sawada M; Moriya M; Sakamoto W; Yogo T
ACS Appl Mater Interfaces; 2010 Jul; 2(7):1903-11. PubMed ID: 20568697
[TBL] [Abstract][Full Text] [Related]
18. Biotechnological approach to induce human fibroblast apoptosis using superparamagnetic iron oxide nanoparticles.
Ferraz FS; López JL; Lacerda SMSN; Procópio MS; Figueiredo AFA; Martins EMN; Guimarães PPG; Ladeira LO; Kitten GT; Dias FF; Domingues RZ; Costa GMJ
J Inorg Biochem; 2020 May; 206():111017. PubMed ID: 32120160
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles on BT-474 human breast cancer cell viability.
Aliakbari M; Mohammadian E; Esmaeili A; Pahlevanneshan Z
Toxicol In Vitro; 2019 Feb; 54():114-122. PubMed ID: 30266435
[TBL] [Abstract][Full Text] [Related]
20. LyP-1-conjugated Fe
Teo P; Wang X; Zhang J; Zhang H; Yang X; Huang Y; Tang J
J Biomater Sci Polym Ed; 2018 Feb; 29(2):181-194. PubMed ID: 29165044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
